1. bookVolumen 31 (2018): Edición 4 (December 2018)
Detalles de la revista
License
Formato
Revista
eISSN
2300-6676
ISSN
2084-980X
Primera edición
30 May 2014
Calendario de la edición
4 veces al año
Idiomas
Inglés
Acceso abierto

Estimation of Endostatin level in pulmonary arterial hypertension patients and its relation with some parameters

Publicado en línea: 03 Jan 2019
Volumen & Edición: Volumen 31 (2018) - Edición 4 (December 2018)
Páginas: 170 - 179
Recibido: 01 Feb 2018
Aceptado: 05 Apr 2018
Detalles de la revista
License
Formato
Revista
eISSN
2300-6676
ISSN
2084-980X
Primera edición
30 May 2014
Calendario de la edición
4 veces al año
Idiomas
Inglés

1. Allen RP, Schelegle ES, Bennett SH. Diverse forms of pulmonary hypertension remodel the arterial tree to a high shear phenotype. Am J Physiol Heart Circ. Physiol. 2014;307(3):H405-17.10.1152/ajpheart.00144.2014Search in Google Scholar

2. Al-Najeem HT, Al-Dujaili AN. Assessment of Bone Morphogentic protein receptor 2 Level in Pulmonary Arterial Hypertension Disease. Res J Pharm Tech. 2017;10(8):2614-8.10.5958/0974-360X.2017.00464.4Search in Google Scholar

3. Al-Najeem HT, Al-Dujaili AN. Assessment of Gremlin-1 Level in Pulmonary arterial hypertension disease. Res J Pharm Tech. 2017;10(11):3803-6.10.5958/0974-360X.2017.00690.4Search in Google Scholar

4. Montani D, Günther S, Dorfmüller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, et al. Pulmonary arterial hypertension. Orphanet J Rare Dis. 2013; 8(97):51-9.10.1186/1750-1172-8-97Search in Google Scholar

5. Fishman AP. Clinical classification of pulmonary hypertension. Clin Chest Med. 2001;22(3):385-91.10.1016/S0272-5231(05)70278-1Search in Google Scholar

6. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology. J Am Coll Cardiol. 2004; 43(12):5S-12S.10.1016/j.jacc.2004.02.03715194173Search in Google Scholar

7. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25):D34-D41.10.1016/j.jacc.2013.10.02924355639Search in Google Scholar

8. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1): S20-S31.10.1016/j.jacc.2009.04.018279032419555855Search in Google Scholar

9. Toshner M, Tajsic T, Morrell NW. Pulmonary hypertension: advances in pathogenesis and treatment. Br Med Bull. 2010;94(1):21-32.10.1093/bmb/ldq01220447940Search in Google Scholar

10. Eddahibi S, Morrell N, d’Ortho MP, Naeije R, Adnot S. Pathobiology of pulmonary arterial hypertension. Eur Respir J. 2002;20(6): 1559-72.10.1183/09031936.02.0008130212503718Search in Google Scholar

11. Ihida-Stansbury K, McKean DM, Lane KB, Loyd JE, Wheeler LA, Morrell NW, et al. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am J Physiol. Lung Cell. Mol Physiol. 2006;291(4):L694-702.10.1152/ajplung.00119.2006Search in Google Scholar

12. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-85.10.1016/S0092-8674(00)81848-6Search in Google Scholar

13. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins. Proc Natl Acad Sci U S A. 2003;100(8):4766-71.10.1073/pnas.0730882100Search in Google Scholar

14. Abdollahi A, Hahnfeldt P, Maercker C, Gröne HJ, Debus J, Ansorge W, et al. Endostatin’s antiangiogenic signaling network. Mol Cell. 2004;13(5):649-63.10.1016/S1097-2765(04)00102-9Search in Google Scholar

15. Kantola T. Systemic inflammation in colorectal cancer the role of cytokines and endostatin. Finland: Ph D Thesis, Univ Ouluensis 2016: 86pp.Search in Google Scholar

16. Ribatti D, Crivellato E. Immune cells and angiogenesis. J Cell Mol Med. 2009;13(9a):2822-33.10.1111/j.1582-4934.2009.00810.xSearch in Google Scholar

17. Tabruyn SP, Griffioen AW. Molecular pathways of angiogenesis inhibition. Biochem. Biophys Res. 2007;355(1):1-5.Search in Google Scholar

18. Hohenester E, Sasaki T, Olsen BR, Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolution. EMBO J. 1998;17(6):1656-64.10.1093/emboj/17.6.1656Search in Google Scholar

19. Dixelius J, Cross MJ, Matsumoto T, Claesson-Welsh L. Endostatin action and intracellular signaling: β-catenin as a potential target? Cancer Letters. 2003;196(1):1-2.10.1016/S0304-3835(03)00267-2Search in Google Scholar

20. Kreuger J, Matsumoto T, Vanwildemeersch M, Sasaki T, Timpl R, Claesson‐Welsh L, et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. EMBO J. 2002; 21(23):6303-11.10.1093/emboj/cdf63813694212456637Search in Google Scholar

21. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000;19(6):1187-94.10.1093/emboj/19.6.118730566010716919Search in Google Scholar

22. Sipola A. Effects of Vascular Endothelial Growth Factor (VEGF-A) And Endostatin On Bone. Finland: Ph D Thesis, Univ Ouluensis 2009: 108pp.Search in Google Scholar

23. Belur LR, Podetz-Pedersen KM, Sorenson BS, Hsu AH, Parker JB, Carlson CS, et al. Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System. Mol Cancer. 2011;10(1):14.10.1186/1476-4598-10-14304536321310067Search in Google Scholar

24. Jing Y, Lu H, Wu K, Subramanian IV, Ramakrishnan S. Inhibition of ovarian cancer by RGD‐P125A‐endostatin‐Fc fusion proteins. Int J Cancer. 2011;129(3):751-61.10.1002/ijc.25932315609021225621Search in Google Scholar

25. Shin SU, Cho HM, Merchan JR, Zhang J, Kovacs K, Jing Y, et al. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced anti-tumor efficacy. Mol Cancer Ther. 2011;10(4):603-614.10.1158/1535-7163.MCT-10-080421393427Search in Google Scholar

26. Tysome JR, Briat A, Alusi G, Cao F, Gao D, Yu J, et. al. Lister strain of vaccinia virus armed with endostatin–angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther. 2009;16(10):1223.10.1038/gt.2009.74276296219587709Search in Google Scholar

27. Tysome JR, Wang P, Alusi G, Briat A, Gangeswaran R, Wang J, et al. Lister Vaccine Strain of Vaccinia Virus Armed with the Endostatin– Angiostatin Fusion Gene: An Oncolytic Virus Superior to dl 1520 (ONYX-015) for Human Head and Neck Cancer. Hum Gene Ther. 2011;22(9):1101-8.10.1089/hum.2010.17221361787Search in Google Scholar

28. Ho AS, Chen CH, Cheng CC, Wang CC, Lin HC, Luo TY, et al. Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers. Oncotarget. 2014;5(2):473-80.10.18632/oncotarget.1631396422224457622Search in Google Scholar

29. Reiseter S, Molberg Ø, Gunnarsson R, Lund MB, Aalokken TM, Aukrust P, et al. Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: an observational study. Arthritis Res Ther. 2015;17(1):231.10.1186/s13075-015-0756-5455156226315510Search in Google Scholar

30. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-4.10.1136/ard.2006.066068195511417329309Search in Google Scholar

31. Viswanath V, Phiske MM, Gopalani VV. Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol. 2013;58(4):255-268.10.4103/0019-5154.113930372687023918994Search in Google Scholar

32. Murray LA, Rubinowitz A, Herzog EL. Interstitial lung disease: is interstitial lung disease the same as scleroderma lung disease? Curr Opin Rheumatol. 2012;24(6):656-62.10.1097/BOR.0b013e3283588de422955020Search in Google Scholar

33. Seppinen L, Pihlajaniemi T. The multiple functions of collagen XVIII in development and disease. Matrix Biol. 2011;30(2):83-92.10.1016/j.matbio.2010.11.00121163348Search in Google Scholar

34. Flåm ST, Gunnarsson R, Garen T, Norwegian MCTD Study Group, Lie BA, Molberg Ø. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology. 2014;54(3):528-35.10.1093/rheumatology/keu31025187641Search in Google Scholar

35. Anwar A, Ruffenach G, Mahajan A, Eghbali M, Umar S. Novel biomarkers for pulmonary arterial hypertension. Respir Res. 2016; 17(1):88.10.1186/s12931-016-0396-6495525527439993Search in Google Scholar

36. Damico R, Kolb TM, Valera L, Wang L, Housten T, Tedford RJ, et al. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015;191(2):208-18.10.1164/rccm.201409-1742OC434743925489667Search in Google Scholar

37. Färkkilä A. Molecular Studies on Pathogenesis, Prognostic Factors, and New Treatment Options for Ovarian Granulosa Cell Tumors. Finland: Ph D Thesis, Univ Helsinki 2012: 86pp.Search in Google Scholar

38. Freedman DS, Horlick M, Berenson GS. A comparison of the Slaughter skinfold-thickness equations and BMI in predicting body fatness and cardiovascular disease risk factor levels in children 1-4. Am J Clin Nutr. 2013;98(6):1417-24.10.3945/ajcn.113.065961383153424153344Search in Google Scholar

39. Rothberg AE, McEwen LN, Kraftson AT, Ajluni N, Fowler CE, Nay CK, et al. Impact of weight loss on waist circumference and the components of the metabolic syndrome. BMJ Open Diabetes Res Care. 2017;5(1):e000341.10.1136/bmjdrc-2016-000341533767828316795Search in Google Scholar

40. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2015;37(1):67-119.10.1093/eurheartj/ehv31726320113Search in Google Scholar

41. Alhabeeb W, Idrees MM, Ghio S, Kashour T. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension due to left heart disease. Ann Thorac Med. 2014;9(Suppl 1):S47-S55.10.4103/1817-1737.134026411427625076997Search in Google Scholar

42. McNeil K, Dunning J, Morrell NW. The pulmonary physician in critical care• 13: The pulmonary circulation and right ventricular failure in the ITU. Thorax. 2003;58(2):157-62.10.1136/thorax.58.2.157174656212554902Search in Google Scholar

43. Marek-Trzonkowska N, Kwieczyńska A, Reiwer-Gostomska M, Koliński T, Molisz A, Siebert J. Arterial hypertension is characterized by imbalance of pro-angiogenic versus anti-angiogenic factors. PLoS ONE. 2015;10(5):e0126190.10.1371/journal.pone.0126190442385725951297Search in Google Scholar

44. Gouya G, Siller-Matula JM, Fritzer-Szekeres M, Neuhold S, Storka A, Neuhofer LM, et al. Association of endostatin with mortality in patients with chronic heart failure. Eur J Clin Invest. 2014;44(2): 125-35.10.1111/eci.1219724188329Search in Google Scholar

45. Galambos C, Minic AD, Bush D, Nguyen D, Dodson B, Seedorf G, et al. Increased lung expression of anti-angiogenic factors in down syndrome: potential role in abnormal lung vascular growth and the risk for pulmonary hypertension. PLoS ONE. 2016;11(8):e0159005.10.1371/journal.pone.0159005497238427487163Search in Google Scholar

46. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-87.10.1378/chest.09-114019837821Search in Google Scholar

47. Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179(9): 835-42.10.1164/rccm.200809-1472OC267556819218192Search in Google Scholar

48. White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, et al. Activity of the estrogen metabolising enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation. 2012;126(9):1087-98.10.1161/CIRCULATIONAHA.111.06292722859684Search in Google Scholar

49. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, et al. Alterations in estrogen metabolism: Implications for higher penetrance of FPAH in females. Eur Respir J. 2009;34(5):1093-99.10.1183/09031936.00010409374212419357154Search in Google Scholar

50. Lahm T, Albrecht M, Fisher AJ, Selej M, Patel NG, Brown JA, et al. 17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor–mediated effects. Am J Respir Crit Care Med. 2012;185(9):965-80.10.1164/rccm.201107-1293OC335994122383500Search in Google Scholar

51. Asai K, Kanazawa H, Otani K, Shiraishi S, Hirata K, Yoshikawa J. Imbalance between vascular endothelial growth factor and endostatin levels in induced sputum from asthmatic subjects. J Allergy Clin. Immunol. 2002;110(4):571-5.Search in Google Scholar

52. Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JS, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012;186(8):790-6.10.1164/rccm.201203-0383OC22798320Search in Google Scholar

53. Weissmann N, Tadić A, Hänze J, Rose F, Winterhalder S, Nollen M, et al. Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H2O2? Am J Physiol Lung Cell Mol Physiol. 2000; 279(4):L683-90.10.1152/ajplung.2000.279.4.L68311000128Search in Google Scholar

54. Michelakis ED, Rebeyka I, Wu X, Nsair A, Thébaud B, Hashimoto K, et al. O2 Regulation of Voltage-gated K+ Channels in Smooth Muscle Cells by a Mitochondrial Redox Sensor. 2: Regulation of Voltage-gated K+ Channels in Smooth Muscle Cells by a Mitochondrial Redox Sensor Sensing in the Human Ductus Arteriosus: Regulation of Voltage-gated K+ Channels in Smooth Muscle Cells by a Mitochondrial Redox Sensor. Cir Res: J Amer Heart Assoc. 2002;91(6): 478-86.10.1161/01.RES.0000035057.63303.D1Search in Google Scholar

55. Zhao L, Wang J, Wang L, Liang YT, Chen YQ, Lu WJ, et al. Remodeling of rat pulmonary artery induced by chronic smoking exposure. J Thorac Dis. 2014;6(6):818.Search in Google Scholar

56. Wright JL, Tai H, Wang R, Wang X, Churg A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-α signaling. Am. J Physiol Lung Cell Mol Physiol. 2007;292(1):L125-33.10.1152/ajplung.00539.200516905636Search in Google Scholar

57. Mitsuma W, Kodama M, Hanawa H, Ito M, Ramadan MM, Hirono S, et al. Serum endostatin in the coronary circulation of patients with coronary heart disease and its relation to coronary collateral formation. Am J Physiol Heart Circ. Physiol. 2007;99(4):494-8.Search in Google Scholar

58. Sodha NR, Clements RT, Boodhwani M, Xu SH, Laham RJ, Bianchi C, et al. Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am J Physiol Heart Circ Physiol. 2009;296(2): H428-34.10.1152/ajpheart.00283.2008264388419074676Search in Google Scholar

59. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, DucolonÉ A, et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(2):219-24.10.1164/ajrccm.164.2.200612911463591Search in Google Scholar

60. Nilsson I, Shibuya M, Wennström S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res. 2004;299(2):476-85.10.1016/j.yexcr.2004.06.00515350545Search in Google Scholar

61. Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002;19(4): 632-8.10.1183/09031936.02.0024590211998991Search in Google Scholar

62. Menzel O, Bekkeheien RC, Reymond A, Fukai N, Boye E, Kosztolanyi G, et al. Knobloch syndrome: novel mutations in COL18A1, evidence for genetic heterogeneity, and a functionally impaired polymorphism in endostatin. Hum Mutat. 2004;23(1):77-84.10.1002/humu.1028414695535Search in Google Scholar

63. Vogel-Claussen J, Skrok J, Shehata ML, Singh S, Sibley CT, Boyce DM, et al. Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension. Radiol. 2011;258(1):119-27.10.1148/radiol.10100725300938620971775Search in Google Scholar

64. Ashwell M, Gibson S. Waist-to-height ratio as an indicator of ‘early health risk’: simpler and more predictive than using a ‘matrix’based on BMI and waist circumference. BMJ Open. 2016;6(3):e010159.10.1136/bmjopen-2015-010159480015026975935Search in Google Scholar

65. Hammod HJ, Al-Dujaili AN, NooriAl-Dujaili M. Relationship Between Adipocyte Fatty Acid-Binding Protein In Obese Men With Cardiovascular Diseases. Res J Pharm Biol Chem Sci. 2016;7(3):804-8.Search in Google Scholar

66. Hammod HJ, Al-Dujaili AN, Al-Dujaili MN. The Correlation between Cardiovascular Diseases in Obese Men with The Inflammatory Markers: Dyslipidemia, C-Reactive Protein and Tumor Necrosis Factor-alpha. Res J Pharm Biol Chem Sci. 2016;7(3):809-14.Search in Google Scholar

67. Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med. 2007;28(1):1-22.10.1016/j.ccm.2006.11.01217338925Search in Google Scholar

68. Lau EM, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol. 2017;14(10):603.10.1038/nrcardio.2017.8428593996Search in Google Scholar

69. Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Registry to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. Mayo Clin Proc. 2011;86(2):105-112.10.4065/mcp.2010.0394303143421282484Search in Google Scholar

70. Taraseviciute A, Voelkel NF. Severe pulmonary hypertension in postmenopausal obese women. Eur J Med Res. 2006;11(5):198-202.Search in Google Scholar

71. Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179(6):509-16.10.1164/rccm.200807-1195OC19136371Search in Google Scholar

72. Zeng WJ, Sun YJ, Gu Q, Xiong CM, Li JJ, He JG. The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension. Pulm Circ. 2012;2(3):373-8.10.4103/2045-8932.101655348730623130106Search in Google Scholar

Artículos recomendados de Trend MD

Planifique su conferencia remota con Sciendo